Opus Genetics
IRD
29 hedge funds and large institutions have $4.16M invested in Opus Genetics in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.
3,228% more capital inflows, than outflows
Capital inflows: $3.33M | Capital outflows: $100K
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
7% more funds holding
Funds holding: 27 → 29 (+2)
6.28% more ownership
Funds ownership: 5.65% → 11.92% (+6.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CVI Holdings
Wilmington,
Delaware
|
+$1.88M |
| 2 |
Anson Funds Management
Dallas,
Texas
|
+$739K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$397K |
| 4 |
Renaissance Technologies
New York
|
+$128K |
| 5 |
Bridgeway Capital Management
Houston,
Texas
|
+$60.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Valley Investment Advisors
Goshen,
New York
|
-$36K |
| 2 |
Two Sigma Securities
New York
|
-$24K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$20K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$9K |
| 5 |
Virtu Financial
New York
|
-$8.94K |
IRD Hedge Fund Activity: Q4 2018 in Review
29 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q4 2018, worth a combined $4.16M — up 31% from $3.19M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new IRD positions and 6 closed out — a net gain of 2 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was CVI Holdings, opening a new position worth an estimated $1.88M. The largest seller was Hudson Valley Investment Advisors, exiting entirely with an estimated $36K sold.
- 29 institutional investors held Opus Genetics (IRD) as of Q4 2018, up from 27 in Q3 2018.
- Funds reported $4.16M of Opus Genetics stock for Q4 2018, up 31% quarter-over-quarter.
- 8 funds opened new Opus Genetics positions in Q4 2018 and 6 closed out, a net change of +2 holders.
- The largest Opus Genetics buyer in Q4 2018 was CVI Holdings, an estimated $1.88M added.
- The largest Opus Genetics seller in Q4 2018 was Hudson Valley Investment Advisors, an estimated $36K sold.
Based on aggregated 13F filings for Q4 2018.